23rd May 2014 11:28
LONDON (Alliance News) - Hutchison China MediTech Ltd Friday said its research and development company Hutchison MediPharma Ltd and pharmaceuticals firm AstraZeneca PLC have initiated a global phase II study to evaluate the efficacy and safety of AZD6094, Hutchison's potent and highly selective c-Met inhibitor, in patients with papillary renal cell carcinoma.
Renal cell carcinoma is a type of kidney cancer.
Under the terms of the global licence granted to AstraZeneca by Hutchison MediPharma in 2011, AstraZeneca will now make a "milestone payment" to Hutchison MediPharma and will lead and fund development outside of China.
This trial is an open-label, single-arm, multicentre, Phase II, study designed to evaluate the efficacy and safety of AZD6094 in patients with locally advanced or metastatic PRCC. Approximately 20 centres in the US, Canada, and Europe will participate in the study.
Hutchison China shares were quoted up 2.6% at 851.60 pence Friday. AstraZeneca shares were quoted down 0.3% at 4,264.50 pence Friday morning.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaHutchmed